News | January 30, 2012

Manhattan Isotope Technology Receives License Amendment Approval for Strontium-82

January 30, 2012 — Positron Corp., a molecular imaging healthcare company specializing in the field of nuclear cardiology, announced Jan. 23 that its wholly owned subsidiary, Manhattan Isotope Technology (MIT), received approval for its radioactive materials license amendment. The Texas Department of State Health Services -- Radiation Control Program granted the amendment approval.

This amendment will now permit the receipt and processing of solutions that contain strontium (Sr) -82 and other radioisotopes. Over the next six months, MIT will obtain Sr-82 target solutions from foreign irradiators for final purification into active pharmaceutical ingredient (API) grade Sr-82 at the MIT facility in Lubbock, Texas.

During proton irradiation to produce Sr-82, many other radioisotopes are co-produced. These additional isotopes are removed from Sr-82 during radiochemical processing. The previous MIT radioactive materials license was limited to two radioisotopes: Sr-82 and Sr-85. The new amended license broadens the scope of isotopes permitted on site and allows MIT greater flexibility in this validation phase.

Commenting on the significance of the license approval, MIT President and Positron Pharmaceutical Chief Technical Officer Jason Kitten said, "Positron and MIT are rapidly implementing a new foundation for cardiac PET by increasing the supply and reliability of Sr-82. Positron has designed a superior integrated business model for the reliability and expansion of cardiac PET in the U.S.. With this latest license approval, MIT has significantly accelerated Positron's Sr-82 mission and will begin supporting Sr-82 supply in 2012, further strengthening Positron’s goal of solidifying cardiac PET's progression in the U.S."

For more information: www.positron.com

Related Content

Researchers Trace Parkinson's Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
Blood clots in veins and arteries can lead to heart attack, stroke and pulmonary embolism, which are major causes of...
PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017
In the featured article of the March 2017 issue of The Journal of Nuclear Medicine, researchers demonstrate that a new...
ASNC, SNMMI, position statement, myocardial perfusion PET, coronary artery disease
News | PET Imaging | September 01, 2016
September 1, 2016 — The American Society for Nuclear Cardiology (ASNC) and the Society of...
cardiac PET, myocardial perfusion, PET-CT, cardiac perfusion

A PET-CT cardiac perfusion exam from a Siemens Biograph scanner. The black and white areas of the image show the CT imaging of the anatomy. The colored portion shows the PET overlay on the myocardium and is color-coded to show tracer uptake values. This can show areas of the heart muscle where there are perfusion defects cause by infarcts or coronary artery blockages due to a heart attack and help determine the severity of the ischemia.

Feature | PET Imaging | June 03, 2016 | Dave Fornell
Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enabl
blood clot detection, single scan, rats, radionuclides, Peter Caravan, whole body

The whole body of a rat can be imaged for blood clots with one PET scan (which is overlaid here on an MRI image) using the FBP8 probe. Arrow points to a blood clot. Image courtesy of Peter Caravan, Ph.D.

News | PET Imaging | September 23, 2015
September 23, 2015 — New research de
Overlay Init